In an attempt to solve these discrepancies and integrate the microenvironment in the prognosis algorithms, the Lunenburg Lymphoma Biomarker Consortium confirmed in a homogeneously rituximab-chemotherapy-treated group of patients that lower percentages of CD8+ T cells, CD163+ M2 macrophage areas, EZH2 wild-type status, and gain of chromosome 18 in the initial tumor biopsy specimen were predictors of poor prognosis FL treated with R-CHOP while refuting the prognostic impact of various other markers [134]. This evidence concerns the gene CD8A and neoplasm.